Skip to main
NYXH
NYXH logo

Nyxoah SA (NYXH) Stock Forecast & Price Target

Nyxoah SA (NYXH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Nyxoah's positive outlook is bolstered by a noteworthy gross margin of over 73% in the recent quarter, an increase from 62% in the prior quarter, indicating effective cost management amidst growing sales momentum. The potential approval of the Genio system in the U.S. is anticipated to significantly drive revenue growth, supported by trained physicians and a doubling of sales representatives by the end of 2025. Additionally, the favorable results from the DREAM trial and insights from prior market surveys suggest that the Genio system is well-positioned to capture market share in the expanding hypoglossal nerve stimulation sector.

Bears say

Nyxoah SA faces significant challenges in the European market, which may hinder its growth and penetration in the competitive landscape for sleep-disordered breathing treatments. The company's fourth-quarter 2024 revenue of €1.3 million fell short of expectations, missing estimates of €2.0 million and €1.9 million, indicating potential weaknesses in sales performance. Additionally, factors such as regulatory approval issues, inadequate reimbursement, and emerging competition further exacerbate the concerns regarding the company's financial outlook and overall viability in the market.

Nyxoah SA (NYXH) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nyxoah SA (NYXH) Forecast

Analysts have given Nyxoah SA (NYXH) a Buy based on their latest research and market trends.

According to 6 analysts, Nyxoah SA (NYXH) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nyxoah SA (NYXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.